RNA
Atrium Therapeutics, Inc.
8.00$
+1.7%
vs. previous close
Closing price · As of: Oct 5, 2026
Statements
Cash Flow
All figures as a percentage of revenue in the same period.
Tick rows to compare them in a chart (up to 4)
| Line item | Q3 23 | Q4 23 | Q1 24 | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 | LTM* |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -1,305.6% | 752.4% | -1,986.5% | -3,178.7% | -2,808.9% | -3,359.3% | -7,935.7% | -5,190.2% | -1,251.9% | -2,241.2% | -158.6% | -130.7% | -585.1% | |
| 20.1% | 28.0% | 18.1% | 33.6% | 30.4% | 24.8% | 49.9% | -203.2% | 8.5% | 14.2% | 0.8% | 11.4% | 4.6% | |
| 348.5% | 448.9% | 290.9% | 626.5% | 603.3% | 476.1% | 1,127.5% | 459.0% | 152.5% | 413.5% | 62.2% | 29.7% | 99.2% | |
| 263.1% | 3,141.7% | -291.8% | -198.5% | 257.1% | -207.3% | -1,477.7% | -1,512.1% | -4.1% | 670.5% | -141.2% | 483.4% | -22.1% | |
| 32.8% | 39.4% | 25.8% | 26.0% | 72.9% | 131.7% | 238.6% | 86.9% | 31.2% | 102.3% | 10.7% | 1.2% | 19.2% | |
| -1,117.1% | 2,327.4% | -924.3% | -13,441.0% | -20,651.2% | -2,158.5% | 9,992.9% | 4,821.5% | -4,712.8% | -102.3% | -10.7% | -6,377.7% | -2,175.2% | |
| 1.4% | 1,454.2% | 10,992.0% | 21,844.7% | 14,660.3% | 461.6% | 123.1% | 98.1% | 6,816.6% | 2,343.5% | 1,535.5% | 0.0% | 3,258.0% | |
| -2,421.2% | 4,534.1% | 8,081.2% | 5,225.0% | -8,799.8% | -5,056.1% | 2,182.8% | -267.6% | 851.7% | 3,766.9% | 1,364.1% | -6,498.1% | 587.3% | |
| -1,338.3% | 713.1% | -2,012.3% | -3,204.6% | -2,881.8% | -3,491.0% | -8,174.3% | -5,277.1% | -1,283.0% | -2,343.5% | -169.3% | -131.9% | -604.3% |
LTM = last twelve months (sum of the four most recent quarters).
Data as of: October 5, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.